Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

844 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H, Uehara K, Harada A, Kitatani K, Yabuuchi T, Miyazaki S, Ishihara T, Kawaguchi H, Kubota H, Okada H, Ninomaru T, Shindo C, Hata A. Mayahara H, et al. Among authors: hata a. Radiat Oncol. 2022 Jan 15;17(1):7. doi: 10.1186/s13014-021-01979-z. Radiat Oncol. 2022. PMID: 35033139 Free PMC article.
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
Akamatsu H, Teraoka S, Takamori S, Miura S, Hayashi H, Hata A, Toi Y, Shiraishi Y, Mamesaya N, Sato Y, Furuya N, Oyanagi J, Koh Y, Misumi T, Yamamoto N, Nakagawa K. Akamatsu H, et al. Among authors: hata a. Clin Cancer Res. 2022 Jun 28;28(15):OF1-OF7. doi: 10.1158/1078-0432.CCR-22-0602. Online ahead of print. Clin Cancer Res. 2022. PMID: 35762926 Free PMC article.
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).
Miura S, Nishio M, Akamatsu H, Goto Y, Hayashi H, Gemma A, Yoshino I, Misumi T, Hata A, Hataji O, Fujita K, Seike M, Yanagitani N, Nishino K, Hara S, Saito R, Mori M, Tsuda T, Iwasawa S, Nakagawa S, Mitsudomi T. Miura S, et al. Among authors: hata a. JTO Clin Res Rep. 2023 Feb 24;4(3):100484. doi: 10.1016/j.jtocrr.2023.100484. eCollection 2023 Mar. JTO Clin Res Rep. 2023. PMID: 37034464 Free PMC article.
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K. Yonesaka K, et al. Among authors: hata a. Clin Lung Cancer. 2023 Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3. Clin Lung Cancer. 2023. PMID: 37344331 Clinical Trial.
844 results